BB
BBIO.US BridgeBio Pharma Inc
- Market cap
- USD 15.3B
- P/E
- -
- P/B
- 123.68x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BBIO.US undervalued?
Graham numberThe Graham number of BridgeBio Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BridgeBio Pharma Inc fundamental analysis
No fundamental analysis for BridgeBio Pharma Inc yet.
BridgeBio Pharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NU…
Full company profileBridgeBio Pharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BridgeBio Pharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 40.6M | 8.25M | 69.7M | 77.6M | 9.30M | 222M | 502M | 1.06B |
| Gross Profit | -260K | - | 38.1M | 8.25M | 66.6M | 74.2M | 6.86M | 218M | 474M | 994M |
| Operating Income | -43.9M | -184M | -266M | -474M | -577M | -512M | -607M | -593M | -569M | -300M |
| EBITDA | -43.6M | -183M | -279M | -467M | -534M | -397M | -565M | -437M | -676M | -342M |
| Net Income | -30.6M | -131M | -260M | -449M | -563M | -481M | -643M | -536M | -729M | -497M |
| EPS | -0.33 | -1.42 | -2.48 | -3.80 | -3.90 | -3.26 | -3.95 | -2.88 | -3.70 | -2.54 |
| Balance Sheet | ||||||||||
| Total Assets | 98.0M | 465M | 632M | 704M | 1.01B | 623M | 546M | 919M | 936M | 2.16B |
| Total Liabilities | 153M | 566M | 156M | 596M | 1.88B | 1.87B | 1.89B | 2.38B | 3.01B | 3.82B |
| Shareholders' Equity | -58.0M | -164M | 408M | 57.9M | -870M | -1.25B | -1.35B | -1.47B | -2.08B | -1.66B |
| Cash & Short-term Investments | 92.0M | 436M | 546M | 607M | 837M | 472M | 435M | 681M | 587M | 1.54B |
| Total Debt | 144M | 54.5M | 91.8M | 496M | 1.73B | 1.72B | 1.74B | 1.73B | 2.73B | 2.49B |
| Cash Flow | ||||||||||
| Operating Cash Flow | -40.5M | -137M | -254M | -400M | -498M | -419M | -528M | -521M | -446M | -417M |
| Capital Expenditure | 464K | 18.2M | 5.14M | 7.52M | 48.2M | 6.32M | 1.31M | 933K | 1.10M | 1.07M |
| Free Cash Flow | -41.0M | -155M | -259M | -407M | -546M | -426M | -529M | -522M | -447M | -418M |
| Ratios | ||||||||||
| ROE | - | - | -63.8% | -774.9% | - | - | - | - | - | - |
| ROA | -31.2% | -28.1% | -41.2% | -63.8% | -55.5% | -77.2% | -117.7% | -58.3% | -77.9% | -23.0% |
| Net Profit Margin | - | - | -642.1% | -5,439.7% | -806.9% | -619.7% | -6,913.9% | -241.4% | -145.3% | -47.1% |
| Debt to Equity | - | - | 0.22x | 8.56x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BridgeBio Pharma Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 3.82M | 0.03 | - |
| 2020 | USD 537M | 4.55 | - |
| 2019 | USD 997K | 0.01 | - |
| 2018 | - | - | - |
| 2017 | USD 1.15M | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns BridgeBio Pharma Inc
- Insiders 3.93%
- Institutions 96.08%
- Public & others 0.00%
- Shares outstanding 195M
- Free float 167M
Top funds holding BBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Blue Owl Credit Income Corp D | 7.62M | 3.91% | +79.15% | Mar 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 5.62M | 2.88% | +0.10% | Sep 2026 |
| Vanguard Health Care Inv | 4.64M | 2.38% | +75.89% | Sep 2026 |
| Vanguard Small Cap Index | 3.96M | 2.03% | -2.36% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 2.20M | 1.13% | -5.40% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.08M | 1.07% | +2.68% | Oct 2026 |
| Janus Henderson Enterprise D | 1.91M | 0.98% | 0.00% | Sep 2026 |
| Vanguard Explorer Inv | 1.73M | 0.89% | +0.12% | Sep 2026 |
| Janus Henderson Global Life Sciences D | 1.68M | 0.86% | +4.95% | Sep 2026 |
| Janus Global Life Science AUSD | 1.64M | 0.84% | +9.45% | Sep 2026 |
| JPMorgan Mid Cap Growth I | 1.55M | 0.80% | -1.56% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 1.54M | 0.79% | +2.13% | Aug 2026 |
| iShares Biotechnology ETF | 1.36M | 0.70% | -0.33% | Oct 2026 |
| Invesco Discovery A | 1.22M | 0.63% | -11.38% | Sep 2026 |
| Polar Capital Biotech S Inc | 1.18M | 0.61% | 0.00% | Sep 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 1.11M | 0.57% | +12.10% | Jun 2026 |
| Pictet-Biotech P USD | 1.00M | 0.51% | +11.13% | Sep 2026 |
| Franklin DynaTech Fund A | 1.00M | 0.51% | 0.00% | Sep 2026 |
| Janus Henderson Triton D | 950K | 0.49% | 0.00% | Sep 2026 |
Top institutions holding BBIO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jupiter Topco LLC | 14.1M | 7.24% | 0.00% | Jun 2026 |
| Kohlberg Kravis Roberts & Co LP | 13.3M | 6.81% | 0.00% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 10.7M | 5.51% | +14.71% | Jun 2026 |
| BlackRock Inc | 10.3M | 5.28% | -27.59% | Jun 2026 |
| Viking Global Investors LP | 9.95M | 5.11% | -15.99% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.90M | 4.05% | +1.80% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 7.66M | 3.93% | -5.25% | Jun 2026 |
| Wellington Management Company LLP | 5.31M | 2.73% | +113.73% | Jun 2026 |
| Two Sigma Investments LLC | 4.72M | 2.42% | +51.32% | Jun 2026 |
| Aisling Capital Management LP | 4.59M | 2.36% | -9.82% | Jun 2026 |
| State Street Corp | 4.44M | 2.28% | -10.10% | Jun 2026 |
| Citadel Advisors Llc | 3.76M | 1.93% | +18.47% | Jun 2026 |
| Amvescap Plc. | 3.70M | 1.90% | -19.42% | Jun 2026 |
| D. E. Shaw & Co LP | 3.63M | 1.87% | +42.72% | Jun 2026 |
| Geode Capital Management, LLC | 3.42M | 1.75% | -30.49% | Jun 2026 |
| Jane Street Group LLC | 2.93M | 1.51% | +66.94% | Jun 2026 |
| JPMorgan Chase & Co | 2.40M | 1.23% | +82.74% | Jun 2026 |
| Adage Capital Partners Gp LLC | 2.25M | 1.16% | +275.96% | Jun 2026 |
| Franklin Templeton Inc | 2.16M | 1.11% | -11.43% | Jun 2026 |
| Polar Capital Holdings PLC | 2.06M | 1.06% | -18.09% | Jun 2026 |
BridgeBio Pharma Inc company profile
- Company name
- BridgeBio Pharma Inc
- Ticker
- BBIO.US
- Exchange
- USA Stocks
- Listed since
- Jun 27, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,081
- Fiscal year end
- December
- Address
- 3160 Porter Drive, Palo Alto, CA, United States, 94304
- Phone
- 650 391 9740
- Website
- bridgebio.com
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
BridgeBio Pharma Inc management
10- Dr. Neil Kumar Ph.D.Co-Founder, CEO & Director · born 1979
- Dr. Thomas Trimarchi Ph.D.CFO & President · born 1985
- Dr. Charles J. Homcy M.D.Co-Founder, Chairman of Pharmaceuticals & Lead Director · born 1948
- Dr. Frank P. McCormick Ph.D.Co-Founder, Chairman of Oncology & Director · born 1950
- Ms. Maricel M. ApuliChief Accounting Officer · born 1977
- Dr. Uma Sinha Ph.D.Chief Scientific Officer · born 1958
- Dr. Richard H. Scheller Ph.D.Chairman of Research & Development · born 1953
- Mr. Eli M. Wallace Ph.D.Chief Scientific Officer of Oncology · born 1967
- Dr. Eric Michael David J.D., M.D., Ph.D.Chief Executive Officer of Gene Therapy · born 1972
- Mr. Matthew Outten CPC, MBAChief Commercial Officer · born 1974